Patent 11752200 was granted and assigned to EnClear Therapies on September, 2023 by the United States Patent and Trademark Office.
Disclosed is a method for treating a subject having a neurological disorder characterized by the presence of toxic proteins comprising contacting the cerebrospinal fluid (CSF) of the subject with an agent capable of removing or degrading the toxic protein.